| ASSET | YEAR | % RETURN |
|---|---|---|
Erasca (ERAS) | 2026 | 385.98% |
Twist Bioscience (TWST) | 2026 | 345.57% |
Immunitybio (IBRX) | 2026 | 298.51% |
Aehr Test Systems (AEHR) | 2026 | 284.44% |
10X Genomics (TXG) | 2026 | 277.31% |
Enliven Therapeutics (ELVN) | 2026 | 273.29% |
MaxLinear (MXL) | 2026 | 246.21% |
Pulse Biosciences (PLSE) | 2026 | 243.96% |
AXT (AXTI) | 2026 | 240.87% |
Abcellera Biologics (ABCL) | 2026 | 231.87% |
Hyperliquid Strategies Inc Common Stock (PURR) | 2026 | 228.9% |
Maase (MAAS) | 2026 | 206.48% |
Definium Therapeutics (DFTX) | 2026 | 203.56% |
Oruka Therapeutics (ORKA) | 2026 | 200.71% |
Sellas Life Sciences (SLS) | 2026 | 196.85% |
Applied Opt (AAOI) | 2026 | 192.28% |
Amylyx Pharmaceuticals (AMLX) | 2026 | 189.5% |
Ichor (ICHR) | 2026 | 188.93% |
Iovance Biotherapeutics (IOVA) | 2026 | 188.13% |
Veradermics (MANE) | 2026 | 188.03% |
Spyre Therapeutics (SYRE) | 2026 | 175.82% |
Iridium Communications (IRDM) | 2026 | 168.45% |
Ultra Clean (UCTT) | 2026 | 165.8% |
PBF Energy (PBF) | 2026 | 165.63% |
CareDx (CDNA) | 2026 | 164.28% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.